Matches in SemOpenAlex for { <https://semopenalex.org/work/W2597751388> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2597751388 abstract "5073 Background: Cabo is a multitargeted kinase inhibitor that has demonstrated complete and partial responses in mCRPC as assessed byTc-99 MDP bone scintigraphy. FDG and FDHT PET/CT demonstrate glucose metabolism and androgen receptor binding, respectively. We are exploring these tracers as response biomarkers in mCRPC treated with cabo. Methods: Patients (pts) treated with cabo were scanned with FDHT and FDG PET at baseline and after 6, 12, and 24 weeks (wks) of treatment. 5 index lesions were selected at baseline for each PET modality. The hottest slices from each were averaged (SUVmaxavg) and measured on post-treatment scans. The concordance of the post-treatment alterations of the two tracers (rise vs. decline) was examined, as were PSA alterations. Results: All 16 pts had FDG avid and 15 had FDHT avid disease. Baseline median FDHTmaxavg was 10.84 (3.52 – 18.52) and FDGmaxavg was 6.26 (2.74 – 14.7). Post-treatment alterations are described (Table). Conclusions: Most pts with mCRPC demonstrate diminution of FDHT uptake after 6 and 12 wks of treatment with cabo. These declines are matched by FDG 50-60% of the time, and correlate with PSA declines even less frequently. The etiology of the extent and degree of FDHT declines, and lack of concordance with post-treatment PSA changes, warrant further investigation, and correlation with other imaging modalities and clinical outcomes. Clinical trial information: NCT00588185. [Table: see text]" @default.
- W2597751388 created "2017-04-07" @default.
- W2597751388 creator A5002358672 @default.
- W2597751388 creator A5002973886 @default.
- W2597751388 creator A5015396908 @default.
- W2597751388 creator A5015672299 @default.
- W2597751388 creator A5017288060 @default.
- W2597751388 creator A5020180252 @default.
- W2597751388 creator A5021013894 @default.
- W2597751388 creator A5050136149 @default.
- W2597751388 creator A5072850546 @default.
- W2597751388 creator A5082878792 @default.
- W2597751388 creator A5090778997 @default.
- W2597751388 date "2013-05-20" @default.
- W2597751388 modified "2023-10-12" @default.
- W2597751388 title "Post-treatment alterations in 18F-dihydrotestosterone (FDHT) and FDG PET/CT in metastatic castration-resistant prostate cancer (mCRPC) treated with cabozantinib." @default.
- W2597751388 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.5073" @default.
- W2597751388 hasPublicationYear "2013" @default.
- W2597751388 type Work @default.
- W2597751388 sameAs 2597751388 @default.
- W2597751388 citedByCount "1" @default.
- W2597751388 countsByYear W25977513882014 @default.
- W2597751388 crossrefType "journal-article" @default.
- W2597751388 hasAuthorship W2597751388A5002358672 @default.
- W2597751388 hasAuthorship W2597751388A5002973886 @default.
- W2597751388 hasAuthorship W2597751388A5015396908 @default.
- W2597751388 hasAuthorship W2597751388A5015672299 @default.
- W2597751388 hasAuthorship W2597751388A5017288060 @default.
- W2597751388 hasAuthorship W2597751388A5020180252 @default.
- W2597751388 hasAuthorship W2597751388A5021013894 @default.
- W2597751388 hasAuthorship W2597751388A5050136149 @default.
- W2597751388 hasAuthorship W2597751388A5072850546 @default.
- W2597751388 hasAuthorship W2597751388A5082878792 @default.
- W2597751388 hasAuthorship W2597751388A5090778997 @default.
- W2597751388 hasConcept C121608353 @default.
- W2597751388 hasConcept C126322002 @default.
- W2597751388 hasConcept C126838900 @default.
- W2597751388 hasConcept C143998085 @default.
- W2597751388 hasConcept C2776235491 @default.
- W2597751388 hasConcept C2780192828 @default.
- W2597751388 hasConcept C2781064419 @default.
- W2597751388 hasConcept C2781190966 @default.
- W2597751388 hasConcept C2989005 @default.
- W2597751388 hasConcept C71924100 @default.
- W2597751388 hasConceptScore W2597751388C121608353 @default.
- W2597751388 hasConceptScore W2597751388C126322002 @default.
- W2597751388 hasConceptScore W2597751388C126838900 @default.
- W2597751388 hasConceptScore W2597751388C143998085 @default.
- W2597751388 hasConceptScore W2597751388C2776235491 @default.
- W2597751388 hasConceptScore W2597751388C2780192828 @default.
- W2597751388 hasConceptScore W2597751388C2781064419 @default.
- W2597751388 hasConceptScore W2597751388C2781190966 @default.
- W2597751388 hasConceptScore W2597751388C2989005 @default.
- W2597751388 hasConceptScore W2597751388C71924100 @default.
- W2597751388 hasLocation W25977513881 @default.
- W2597751388 hasOpenAccess W2597751388 @default.
- W2597751388 hasPrimaryLocation W25977513881 @default.
- W2597751388 hasRelatedWork W103692834 @default.
- W2597751388 hasRelatedWork W2071633854 @default.
- W2597751388 hasRelatedWork W2093570182 @default.
- W2597751388 hasRelatedWork W2097685890 @default.
- W2597751388 hasRelatedWork W2208957248 @default.
- W2597751388 hasRelatedWork W2248499526 @default.
- W2597751388 hasRelatedWork W2558745955 @default.
- W2597751388 hasRelatedWork W2591484212 @default.
- W2597751388 hasRelatedWork W2767214731 @default.
- W2597751388 hasRelatedWork W2790003199 @default.
- W2597751388 hasRelatedWork W2892587677 @default.
- W2597751388 hasRelatedWork W2947775727 @default.
- W2597751388 hasRelatedWork W3006787367 @default.
- W2597751388 hasRelatedWork W3007977248 @default.
- W2597751388 hasRelatedWork W3083964465 @default.
- W2597751388 hasRelatedWork W3122736435 @default.
- W2597751388 hasRelatedWork W3159216873 @default.
- W2597751388 hasRelatedWork W3193588050 @default.
- W2597751388 hasRelatedWork W3203882531 @default.
- W2597751388 hasRelatedWork W980447132 @default.
- W2597751388 isParatext "false" @default.
- W2597751388 isRetracted "false" @default.
- W2597751388 magId "2597751388" @default.
- W2597751388 workType "article" @default.